TY - JOUR
T1 - Emerging new cell therapies/immune therapies in B-cell non-Hodgkin's lymphoma
AU - Banerjee, Titas
AU - Vallurupalli, Anusha
N1 - Funding Information:
Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Publisher Copyright:
© 2021
PY - 2022/2
Y1 - 2022/2
N2 - Abstract:Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating in B-lymphocytes, T-lymphocytes, or natural killer (NK) lymphocytes. First line therapy is well established and generally a combination of steroids and chemotherapy. Treatment of relapsed/refractory (R/R) NHL however remains a challenge with rapidly evolving new therapies. Many of these new therapies focus on manipulating the body's natural immune mechanisms to identify and eradicate tumor cells. There has been much success with using checkpoint inhibitors in Hodgkin's Lymphoma (HL). However, results have been modest in NHL, prompting further studies of immunomodulatory strategies to target NHL. In this article, we review the emerging immune and cell therapies for R/R B-NHL including checkpoint inhibitors, bispecific antibodies, chimeric antigen receptor (CAR) T-cell therapy, and small molecule inhibitors both alone and in combination.
AB - Abstract:Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating in B-lymphocytes, T-lymphocytes, or natural killer (NK) lymphocytes. First line therapy is well established and generally a combination of steroids and chemotherapy. Treatment of relapsed/refractory (R/R) NHL however remains a challenge with rapidly evolving new therapies. Many of these new therapies focus on manipulating the body's natural immune mechanisms to identify and eradicate tumor cells. There has been much success with using checkpoint inhibitors in Hodgkin's Lymphoma (HL). However, results have been modest in NHL, prompting further studies of immunomodulatory strategies to target NHL. In this article, we review the emerging immune and cell therapies for R/R B-NHL including checkpoint inhibitors, bispecific antibodies, chimeric antigen receptor (CAR) T-cell therapy, and small molecule inhibitors both alone and in combination.
KW - Bispecific Antibodies
KW - CAR-T Therapy
KW - Checkpoint Inhibitors
KW - Immunotherapy
KW - Non-Hodgkin's Lymphoma
KW - Novel Therapy
KW - Small molecule inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85122950416&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122950416&partnerID=8YFLogxK
U2 - 10.1016/j.currproblcancer.2021.100825
DO - 10.1016/j.currproblcancer.2021.100825
M3 - Article
C2 - 35033383
AN - SCOPUS:85122950416
SN - 0147-0272
VL - 46
JO - Current Problems in Cancer
JF - Current Problems in Cancer
IS - 1
M1 - 100825
ER -